Fig. 2: Siglec-15 and PD-L1 predict DFS in non-metastasis LUAD. | Cancer Gene Therapy

Fig. 2: Siglec-15 and PD-L1 predict DFS in non-metastasis LUAD.

From: Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma

Fig. 2

A Comparison of the staining percentage of Siglec-15 and PD-L1 in patients with and without lymph node metastasis. The bar indicates mean with 95% CI. B Comparison of the staining percentage of Siglec-15 and PD-L1 in patients without lymph node metastasis developed recurrence and non-recurrence. The bar indicates mean with 95% CI. C, D Comparison of DFS between non-metastasis LUAD patients with Siglec-15/PD-L1 positivity and negativity. E, F Comparison of DFS between non-metastasis LUAD patients with TC-Siglec-15 or Mφ-Siglec-15 positivity and negativity. G, H Comparison of DFS between non-metastasis LUAD patients with TC-PD-L1 or NTC-PD-L1 positivity or negativity. *p < 0.05, **p < 0.01 and ***p < 0.001.

Back to article page